"instanceType","label","id","description","uuid:ID","rationale","name"
"StudyDesign","","StudyDesign_1","The main design for the study","8cb9f6d0-cf25-4319-8260-16b0fd77f2e7","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1"
